医薬品開発におけるバイオマーカーのジャーナル オープンアクセス

抽象的な

In the Development of Psychiatric Drugs, New Approaches are Being Used

V.B Karsdal*

Insight into the functional processes that underpin central nervous system (CNS) dysfunction in psychiatric disorder is currently being bolstered by neuroscience. An increasing number of potential 'drugable' CNS targets have been found using sophisticated mechanism-based techniques, which may help both clinical care of psychiatric diseases and future psychiatric drug development. Psychiatry, on the other hand, has been unable to fully leverage the gains that neuroscience has yielded thus far. It's still unclear how many novel neuroscience-based targets are linked to the symptoms that make up psychiatric diagnostic entities, and stakeholders haven't agreed on how to proceed. Neuroscientists, clinicians, industry, and regulators must collaborate to overcome the translational gaps between novel targets, CNS functions, and clinical occurrences if psychiatry is to improve the condition of patients with psychiatric diseases by using mechanism-based CNS targets.